A meta-analysis by Li, et al. found that the presence of an EGFR mutation confers a survival benefit to NSCLC patients with BMs, which may be explained by their finding that use of EGFRmut-targeted TKIs significantly improved survival in patients with BMs [8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.